Skip to Main Content
Skip Nav Destination
Article navigation

Transient perivascular inflammation of the carotid artery (TIPIC) syndrome is a rare, benign, and usually self-limited condition characterized by acute unilateral cervical pain and focal perivascular inflammation of the carotid artery. Although reported in young to middle-aged adults without underlying systemic disease, occasional associations with autoimmune conditions have been described.

To our knowledge, TIPIC syndrome has never been reported in pediatric populations neither in immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX). We report a unique case documented by high-resolution imaging in a 10-year-old boy with IPEX, a rare monogenic disorder caused by FOXP3 mutations impairing CD4+ regulatory T cell development and/or function. IPEX typically manifests with early-onset autoimmune enteropathy, endocrinopathies, and skin manifestations, though clinical presentations are highly variable. Cervical vascular involvement has not been reported previously in this inborn error of immunity. This case broadens the clinical spectrum of both rare conditions.

A 10-year-old boy with IPEX syndrome related to a hemizygous pathogenic FOXP3 mutation (c.1222G>A; p.V408M) presented with febrile torticollis. IPEX had been diagnosed at the age of 6 mo in the context of bullous pemphigoid. He also presented transient food allergies and allergic asthma and, at the age of 6 years, a nephrotic syndrome related to membranous glomerulonephritis in prolonged remission under sirolimus. He had no autoimmune enteropathy and endocrinopathy, and serial screens for autoantibodies remain negative. The mother, who is a heterozygous carrier for the p.V408M mutation, is healthy, as his father and young sister. Several cousins carrying the same hemizygous FOXP3 mutation presented with skin or renal manifestations, diabetes, and atopic manifestations (asthma, food allergies).

1 mo before admission, the patient developed self-limited gastroenteritis shortly complicated by erythema nodosum, fever, polyarthralgia, and arthritis. He was treated with amoxicillin–clavulanate and a short course of corticosteroids. After corticosteroid withdrawal, fever recurred with nonspecific chest pain, low-grade systemic inflammation (C reactive protein [CRP] ∼15 mg/L), and subsequently acute left-sided neck pain radiating to the ear with reducible torticollis.

Computed tomography (CT) of the head and neck revealed circumferential parietal thickening of the left carotid artery wall (∼4 mm) with mass effect on the adjacent jugular vein, confirmed by ultrasound (US) and magnetic resonance imaging (MRI) (Fig. 1, A–D). Perivascular inflammation also extended to the left subclavian artery. No intracerebral, ocular, or cardiac vascular lesions were identified. Extensive infectious workup, including for syphilis, Coxiella burnetii, Yersinia spp., and fungi, was negative. Autoimmune tests were unremarkable (anti-nuclear antibodies, anti-centromere, anti-extractable nuclear antigen, anticardiolipin, anti-B2GP1 antibodies) except for mildly positive perinuclear anti-neutrophil cytoplasmic antibodies (80 U/ml) with no anti-PR3 or anti-myeloperoxidase (MPO) specificity. The interferon-γ release assay was negative.

Figure 1.
Medical imaging of the head and neck showing carotid artery inflammation at diagnosis and after treatment. One magnetic resonance imaging scan, one computed tomography scan, and four ultrasound images. The images show the left carotid artery inflammation at diagnosis and after four weeks of treatment. Panel A: Axial cervical view of magnetic resonance imaging showing circumferential parietal thickening of the left carotid artery wall with a white arrow indicating the thickening. Panel B: Axial cervical view of computed tomography scan showing the same thickening. Panel C: Ultrasound image showing the thickening with a white arrow. Panel D: Doppler ultrasound image showing the thickening with a color-coded scale indicating blood flow. Panel E: Axial ultrasound view showing regression of wall thickening after treatment, with measurements indicated. Panel F: Longitudinal ultrasound view showing further regression of wall thickening after treatment.

Imaging of perivascular inflammation of the left internal carotid artery at diagnosis and at 4 wk of treatment. (A–F) At diagnosis: circumferential parietal thickening (white arrows) of the left carotid artery wall on axial cervical views of MRI (A), CT scan (B), US (C), and Doppler (D). At midterm treatment: regression of wall thickening on axial (E) and sagittal (F) US views.

Figure 1.
Medical imaging of the head and neck showing carotid artery inflammation at diagnosis and after treatment. One magnetic resonance imaging scan, one computed tomography scan, and four ultrasound images. The images show the left carotid artery inflammation at diagnosis and after four weeks of treatment. Panel A: Axial cervical view of magnetic resonance imaging showing circumferential parietal thickening of the left carotid artery wall with a white arrow indicating the thickening. Panel B: Axial cervical view of computed tomography scan showing the same thickening. Panel C: Ultrasound image showing the thickening with a white arrow. Panel D: Doppler ultrasound image showing the thickening with a color-coded scale indicating blood flow. Panel E: Axial ultrasound view showing regression of wall thickening after treatment, with measurements indicated. Panel F: Longitudinal ultrasound view showing further regression of wall thickening after treatment.

Imaging of perivascular inflammation of the left internal carotid artery at diagnosis and at 4 wk of treatment. (A–F) At diagnosis: circumferential parietal thickening (white arrows) of the left carotid artery wall on axial cervical views of MRI (A), CT scan (B), US (C), and Doppler (D). At midterm treatment: regression of wall thickening on axial (E) and sagittal (F) US views.

Close modal

Oral corticosteroids were restarted (2 mg/kg/day), leading to prompt resolution of fever, pain, and decreasing of CRP levels (from 16.9 to 3.7 mg/L) within 48 h. Treatment was tapered over 8 wk with complete clinical and radiologic remissions. Midterm US demonstrated a complete regression of carotid inflammation (Fig. 1, E and F) and resolution of inflammation in the left subclavian artery. After 18 mo of follow-up, the patient remained asymptomatic with no recurrence.

This unique and unusual presentation of perivasculitis of the left carotid artery fulfilled criteria for TIPIC syndrome, representing the first case reported in IPEX.

TIPIC syndrome, first reported in 1927, is a rare, self-limited vasculitis of carotid bifurcation clinically characterized by acute neck pain (also referred to as carotidynia) and radiologically by eccentric perivascular infiltration without significant endoluminal stenosis. Diagnosis criteria proposed by Lecler et al. in 2017 include: (1) acute unilateral cervical pain in regard to the carotid artery, (2) radiological evidence of perivascular inflammation, (3) exclusion of vascular and non-vascular causes of neck pain, and (4) improvement within 14 days either spontaneously or with anti-inflammatory treatment (1). Laboratory findings are typically unspecified (normal blood counts, and only occasional mildly elevated inflammatory markers) (1). Our patient fulfilled all these criteria with typical clinical and radiologic findings, without evidence of infectious or systemic large-vessel vasculitis.

TIPIC syndrome predominantly affects young to middle-aged adults, usually in the absence of underlying systemic disease. Only a few associations with autoimmune conditions have been described, including ankylosing spondylitis, Hashimoto thyroiditis, Graves’ disease, systemic lupus erythematosus, Sjögren’s syndrome, and rheumatoid arthritis (1). Importantly, no pediatric cases have been reported to date. Although TIPIC syndrome is self-limited with unknown pathophysiology, short courses of anti-inflammatory treatment such as nonsteroidal anti-inflammatory drugs, aspirin, or corticosteroids have been proposed, though no controlled studies exist.

To our knowledge, this is the first case of TIPIC syndrome reported in a patient with IPEX syndrome. IPEX is a primary immunodeficiency caused by mutations in the FOXP3 gene located on the X chromosome. FOXP3 is a transcription factor involved in the development and function of CD4+CD25+ regulatory T cells, which play a critical role in maintaining immune tolerance and preventing autoimmunity. FOXP3 hemizygous mutations lead in males to a severe, early-onset, immune dysregulation syndrome characterized by a wide spectrum of manifestations, such as enteropathy, endocrinopathies, and hematologic abnormalities, but also infections, cutaneous, and renal involvement (2). Of note, to our knowledge, autoimmune vasculitis has never been reported in IPEX patients.

A considerable heterogeneity exists in clinical presentation of IPEX patients. The mutation identified in our patient, i.e., c.1222G>A (p.V408M), located in exon 11, is associated with a milder phenotype and prolonged survival (3, 4). Functional studies suggest a less disruptive effect on FOXP3 protein structure, consistent with the milder course of the disease observed in these patients (3, 4, 5). Prolonged survival in this subgroup may provide sufficient time for the development of atypical autoimmune manifestations such as TIPIC syndrome.

Interestingly, in our patient the onset of carotidynia followed an acute episode of gastroenteritis, which was complicated by immune dysregulation manifestations such as erythema nodosa and arthralgia. This suggests that an infectious trigger may have acted as a facilitating factor on the background of the underlying FOXP3-related immune dysregulation, leading to localized vascular inflammation.

This unique case highlights the potential for atypical inflammatory vascular involvement in IPEX syndrome, suggesting shared immune-inflammatory pathways between both conditions and warranting further investigation into their underlying pathophysiology. Clinicians caring for IPEX patients should be aware of such unusual presentations, particularly in pediatric cases where TIPIC has not been previously described. Early recognition is crucial, as prognosis remains favorable with appropriate supportive and anti-inflammatory management. Multidisciplinary evaluation and systematic use of imaging are essential to ensure accurate diagnosis and optimal outcomes in these complex cases.

Written informed consent was obtained from the patient’s parents for publication of this case report and any accompanying images.

We would like to thank the physicians of the Immuno-Hematology and Rheumatology Department at Necker Hospital and National Referral Center for Rare Systemic Autoimmune Diseases at Cochin Hospital for their assistance in the management of this patient. We also gratefully acknowledge the Radiology Department for their help in obtaining and interpreting the imaging studies. We thank the patient and his family for participating in this study.

Author contributions: Vincent Fréret: conceptualization, data curation, formal analysis, funding acquisition, investigation, methodology, project administration, resources, software, supervision, validation, visualization, and writing—original draft, review, and editing. Klervie Loiselet: conceptualization, resources, visualization, and writing—original draft, review, and editing. Benjamin Terrier: data curation, validation, and writing—review and editing. Marie-Louise Frémond: conceptualization, supervision, and writing—review and editing. Bénédicte Neven: conceptualization, formal analysis, resources, supervision, and writing—original draft, review, and editing. Agathe Escudier: conceptualization, investigation, methodology, project administration, supervision, validation, and writing—review and editing.

1.
Lecler
,
A.
,
M.
Obadia
,
J.
Savatovsky
,
H.
Picard
,
F.
Charbonneau
,
N.
Menjot de Champfleur
,
O.
Naggara
,
B.
Carsin
,
M.
Amor-Sahli
,
J.P.
Cottier
, et al
.
2017
.
TIPIC syndrome: Beyond the myth of carotidynia, a new distinct unclassified entity
.
AJNR Am. J. Neuroradiol.
38
:
1391
1398
.
2.
Park
,
J.H.
,
K.H.
Lee
,
B.
Jeon
,
H.D.
Ochs
,
J.S.
Lee
,
H.Y.
Gee
,
S.
Seo
,
D.
Geum
,
C.A.
Piccirillo
,
M.
Eisenhut
, et al
.
2020
.
Immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome: A systematic review
.
Autoimmun. Rev.
19
:
102526
.
3.
Rubio-Cabezas
,
O.
,
J.A.L.
Minton
,
R.
Caswell
,
J.P.
Shield
,
D.
Deiss
,
Z.
Sumnik
,
A.
Cayssials
,
M.
Herr
,
A.
Loew
,
V.
Lewis
, et al
.
2009
.
Clinical heterogeneity in patients with FOXP3 mutations presenting with permanent neonatal diabetes
.
Diabetes Care
.
32
:
111
116
.
4.
Consonni
,
F.
,
S.
Ciullini Mannurita
, and
E.
Gambineri
.
2021
.
Atypical presentations of IPEX: Expect the unexpected
.
Front. Pediatr.
9
:
643094
.
5.
Kwon
,
H.-K.
,
H.-M.
Chen
,
D.
Mathis
, and
C.
Benoist
.
2018
.
FoxP3 scanning mutagenesis reveals functional variegation and mild mutations with atypical autoimmune phenotypes
.
Proc. Natl. Acad. Sci. USA
.
115
:
E253
E262
.

Author notes

Disclosures: B. Terrier reported personal fees from Novartis, AstraZeneca, GlaxoSmithKline, and CSL Vifor outside the submitted work. No other disclosures were reported.

This article is available under a Creative Commons License (Attribution 4.0 International, as described at https://creativecommons.org/licenses/by/4.0/).

or Create an Account

Close Modal
Close Modal